Verici Dx plc (LON:VRCI – Get Free Report)’s share price reached a new 52-week low on Monday . The stock traded as low as GBX 4 ($0.05) and last traded at GBX 4 ($0.05), with a volume of 210052 shares trading hands. The stock had previously closed at GBX 4.25 ($0.06).
Verici Dx Trading Down 5.9 %
The business’s 50-day simple moving average is GBX 6.44 and its 200-day simple moving average is GBX 7.05. The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.65. The company has a market cap of £9.70 million, a PE ratio of -200.00 and a beta of 1.59.
About Verici Dx
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Featured Articles
- Five stocks we like better than Verici Dx
- Breakout Stocks: What They Are and How to Identify Them
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- 3 Fintech Stocks With Good 2021 Prospects
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- The Basics of Support and Resistance
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
